Should an adult patient with moderate‑to‑severe obstructive sleep apnea (apnea‑hypopnea index ≥15), BMI ≤35 kg/m², CPAP intolerance, and no contraindicating airway collapse pattern or comorbidities undergo hypoglossal nerve stimulation with the Inspire (hypoglossal nerve stimulator) system?

Hypoglossal Nerve Stimulation with Inspire for Moderate-to-Severe OSA

Yes, hypoglossal nerve stimulation (HNS) with the Inspire system should be offered to this patient, as they meet all standard criteria: moderate-to-severe OSA (AHI ≥15), BMI ≤35 kg/m², documented CPAP intolerance, and absence of contraindications. 1

Patient Selection Criteria

The 2021 European Respiratory Society guideline recognizes HNS as an established non-CPAP therapy for OSA, representing a significant advancement since their 2011 statement when neuromuscular stimulation could not be recommended. 1, 2

Essential Inclusion Criteria Met:

• AHI 15-65 events/hour with predominantly obstructive (not central or mixed) apneas 3
• BMI ≤35 kg/m² (stricter cutoff of ≤32 kg/m² shows better specificity for success) 4
• CPAP failure or intolerance documented 1, 3
• Age considerations: Adult patients, typically middle-aged, are ideal candidates 5

Critical Pre-Operative Evaluation Required:

Drug-induced sleep endoscopy (DISE) is mandatory to exclude complete concentric collapse at the palatal level, which predicts poor response to respiratory-synchronous bilateral stimulation systems. 3, 4 Approximately 20% of candidates demonstrate this exclusion pattern, with higher rates in patients with elevated BMI and severe OSA. 4

Efficacy Data

Objective Outcomes:

Recent high-quality evidence demonstrates robust efficacy:

• Bilateral HNS (2025): 63.5% of patients achieved ≥50% AHI reduction with final AHI <20 events/hour, with mean AHI reduction of 18.3 events/hour 6
• Mean AHI improvement: Significant reductions across studies, with oxygen desaturation index improving by 17.7 events/hour 6
• Response rates: 44-92% depending on patient selection, with lower therapeutic PAP requirements (<8 cm H₂O) predicting superior outcomes (92% response rate vs 44% for PAP ≥8 cm H₂O) 5

Patient-Reported Outcomes:

HNS demonstrates sustained improvements in quality of life metrics comparable to or exceeding PAP therapy: 7

• Epworth Sleepiness Scale: Clinically meaningful improvement in 60-65% of patients 7, 8
• Depression (PHQ-9): Significantly greater improvement with HNS compared to PAP (mean difference -1.48 points) 7
• Insomnia Severity Index: 44-47% achieve meaningful improvement 7
• Functional Outcomes of Sleep Questionnaire: 55-59% show clinically meaningful gains 7

Safety Profile

The 2025 bilateral HNS trial reported an acceptable safety profile with serious adverse events in only 8.7% of participants, demonstrating this is a safe surgical intervention. 6 HNS has proven safe even in complex populations including patients with neuromuscular disorders. 9

Adherence Advantage

Device adherence is excellent, averaging 7-8 hours/night at 3-12 months post-implantation, which typically exceeds CPAP adherence rates in intolerant patients. 6, 8 This adherence pattern remains stable regardless of baseline disease severity (mSASI score). 8

Predictors of Success

Favorable Prognostic Factors:

• Lower therapeutic PAP requirement (<8 cm H₂O): Strong positive predictor with 92% response rate 5
• Absence of complete concentric palatal collapse on DISE 3, 4
• Lower BMI: Better outcomes, though patients up to BMI 35 kg/m² can benefit 4
• Younger age without excessive comorbidities 2

Common Pitfalls to Avoid:

• Failing to perform DISE: This is not optional—concentric collapse must be excluded 3, 4
• Inadequate CPAP trial documentation: Ensure intolerance is well-documented before proceeding 1
• Ignoring central apnea component: Significant central/mixed apneas are contraindications 3

Positioning in Treatment Algorithm

HNS is not a salvage procedure but rather a primary alternative for CPAP-intolerant patients. 1 This contrasts with multilevel soft tissue surgery, which the 2011 ERS guideline classified as salvage therapy with unpredictable success. 2 HNS represents a more predictable and effective option than traditional surgical approaches like UPPP, which can only be recommended in carefully selected patients with frequent long-term side-effects. 2

Alternative Considerations

If HNS is contraindicated or declined:

• Mandibular advancement devices: Supported for mild-to-moderate OSA 2
• Maxillomandibular advancement: As efficient as CPAP in young patients without excessive BMI, but more invasive 2

Given this patient's profile meeting all standard criteria, HNS with Inspire should be recommended as the preferred next-line therapy after CPAP failure. 1, 6